NOV03

DRUG4 trials

Sponsors

Novaliq GmbH, Bausch & Lomb Incorporated

Conditions

Dry Eye DiseaseDry Eye Disease (DED)

Phase 2

Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

CompletedNCT03333057

Novaliq GmbHDry Eye Disease (DED)

Start: 2018-01-03End: 2018-07-27Updated: 2022-01-04

Phase 3

Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

CompletedNCT04139798

Bausch & Lomb IncorporatedDry Eye Disease (DED)

Start: 2020-07-20End: 2021-03-12Updated: 2024-10-23

Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)

CompletedNCT04140227

Bausch & Lomb IncorporatedDry Eye Disease (DED)

Start: 2020-09-24End: 2022-01-05Updated: 2024-03-04

Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)

CompletedNCT04567329

Bausch & Lomb IncorporatedDry Eye Disease

Start: 2020-11-18End: 2021-08-30Updated: 2024-08-19

Related Papers

Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials

Frontiers in Ophthalmology2024-11-054 citations

A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solution.

2023-11-018 citations

Addressing excessive evaporation: an unmet need in dry eye disease

The American Journal of Managed Care2023-10-016 citations

Exploring Signs and Symptoms Associated with Meibomian Gland Dysfunction for Use as Clinical Trial Endpoints

Journal of Ocular Pharmacology and Therapeutics2023-08-294 citations